Table 2. Baseline demographics of participants by group and overall.
|
Characteristics |
Treatment Group | Overall | |||||
|---|---|---|---|---|---|---|---|
| 1 mg DNA-IIV3 | 4 mg DNA-IIV3 | IIV3-IIV3 | |||||
| ≥12 to ≤17 yrs (n = 6) | ≥6 to ≤11 yrs (n = 6) | ≥12 to ≤17 yrs (n = 16) | ≥6 to ≤11 yrs (n = 16) | ≥12 to ≤17 yrs (n = 16) | ≥6 to ≤11 yrs (n = 15) | ≥6 to ≤17 yrs (n = 75) | |
| Sex–no. (%) | |||||||
| Male | 2 (33) | 3 (50) | 9 (56) | 8 (50) | 7 (44) | 10 (67) | 39 (52) |
| Female | 4 (67) | 3 (50) | 7 (44) | 8 (50) | 9 (56) | 5 (33) | 36 (48) |
| Age—yearsa | |||||||
| Mean (S.D.) | 14.7 (1.2) | 8.2 (1.5) | 14.2 (1.5) | 9.2 (1.3) | 14.8 (1.9) | 9.1 (1.6) | 11.8 (3.2) |
| Median [Range] | 15 [13,16] | 9 [6,10] | 14 [12,17] | 9 [7,11] | 15 [12,17] | 9 [7,12] | 12 [6,17] |
| Race–no. (%) | |||||||
| Black or African American | 2 (33) | 0 (0) | 2 (12) | 0 (0) | 4 (25) | 4 (27) | 12 (16) |
| White | 4 (67) | 4 (67) | 11 (69) | 15 (94) | 11 (69) | 11 (73) | 56 (75) |
| Multiracial | 0 (0) | 2 (33) | 3 (19) | 1 (6) | 1 (6) | 0 (0) | 7 (9) |
| Ethnicity–no. (%) | |||||||
| Non-Hispanic/Latino | 6 (100) | 5 (83) | 16 (100) | 15 (94) | 16 (100) | 15 (100) | 73 (97) |
| Hispanic/Latino | 0 (0) | 1 (17) | 0 (0) | 1 (6) | 0 (0) | 0 (0) | 2 (3) |
| Body Mass Index (BMI)a | |||||||
| Mean (S.D.) | 21.6 (4.3) | 17.3 (3.0) | 24.1 (4.7) | 18.0 (2.8) | 23.4 (5.6) | 18.2 (3.7) | 20.7 (5.0) |
| Range | [18.3, 27.1] | [13.8, 22.7] | [18.0, 34.2] | [14.0, 24.5] | [16.2, 38.4] | [13.6, 28.2] | [13.6, 38.4] |
| Influenza vaccinations in the previous 5 years–no. (%) | |||||||
| >5 times | 0 (0) | 0 (0) | 3 (19) | 3 (19) | 4 (25) | 2 (13) | 12 (16) |
| 3–5 times | 3 (50) | 1 (17) | 4 (25) | 12 (75) | 4 (25) | 9 (60) | 33 (44) |
| 1–2 times | 1 (17) | 3 (50) | 8 (50) | 0 (0) | 5 (31) | 3 (20) | 20 (27) |
| 0 times | 2 (33) | 2 (33) | 1 (6) | 1 (6) | 3 (19) | 1 (7) | 10 (13) |
aAge, along with height and weight (used for BMI), measured at date of prime vaccination.